Clinical trials
Ureteral Neoplasms trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
55 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2003 | 2 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 5 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 8 |
| 2018 | 5 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 5 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 25 |
| Active, not recruiting | 14 |
| Recruiting | 8 |
| Terminated | 7 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 12 |
| Eli Lilly and Company | 5 |
| M.D. Anderson Cancer Center | 5 |
| Mayo Clinic | 4 |
| Astellas Pharma Global Development, Inc. | 2 |
| Emory University | 2 |
| Fox Chase Cancer Center | 2 |
| Memorial Sloan Kettering Cancer Center | 2 |
| AEterna Zentaris | 1 |
| Achieve Life Sciences | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ureteral Neoplasms | 55 |
| Urinary Bladder Neoplasms | 46 |
| Urethral Neoplasms | 35 |
| Carcinoma, Transitional Cell | 20 |
| Carcinoma, Non-Small-Cell Lung | 7 |
| Carcinoma, Renal Cell | 6 |
| Pancreatic Neoplasms | 6 |
| Prostatic Neoplasms | 6 |
| Esophageal Neoplasms | 5 |
| Lung Neoplasms | 5 |
Trials
Showing 26 to 50 of 55. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.